Archives: Speakers

Richard Osborne is AstroAgency’s Chief Technology Officer. He has extensive industry experience across the space value chain extending back to the early 1990s, previously worked as Programme Manager at an orbital launch company, as well as launch systems, spaceports and propulsion consultancy for companies including Reaction Engines and Airborne Engineering, and systems engineering and analysis for numerous space industry projects including ESA payloads to the Mir space station and NASA Earth Observation and Russian Mars missions. A Chartered Physicist, he has a B.Sc(Hons) in Physics, M.Sc in Remote Sensing and Planetary Physics, studied for a Solar Astrophysics PhD, specialising in stellar magnetohydrodynamics and solar flares, and is a Fellow of the Royal Astronomical Society and British Interplanetary Society

Prof. Dr. Trojan graduated from Medical School in Zurich, Switzerland in 1992. From 1997 to 1999, he was a Research Associate in oncology at the Dana Farber Cancer Institute, Harvard Medical School. As a resident in oncology, Co-Head ABMT-Laboratory, PI and head of a translational research group, Dr. Trojan has spent more than 10 years at the University Hospital of Zurich. He has also continued most of his research at the University of Zurich, with a focus on immunology, pharmacogenetics, and breast cancer.

Furthermore, he was assigned as the leading oncologist for Breast Centers in Zurich and has conducted a variety of clinical trials involving patient communication and shared decision making, with integration of electronic patient reported outcomes (ePROs). Dr. Trojan now holds a titular professorship at the University of Zurich medical faculty and has been awarded with national and international prizes for his patient-centered work and outcome research. He is the founder of Mobile Health AG, as well as the initiator of a number of randomized trials and registries involving the Medidux^TM app for ePROs. Currently, Dr. Trojan focuses on patient@home digital support, study registries for biosimilars and implementation of decentralized clinical trials.